NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Yen Chia Jui
AD Scientific Index 2024
Others
National Cheng Kung University - Tainan City / Taiwan
國立成功大學
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Yen Chia Jui's MOST POPULAR ARTICLES
1-)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 16942019
2-)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo … AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The lancet oncology 20 (2), 282-296, 2019 12272019
3-)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 9682018
4-)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double …AX Zhu, JO Park, BY Ryoo, CJ Yen, R Poon, D Pastorelli, JF Blanc, ...The lancet oncology 16 (7), 859-870, 20158982015
5-)
The crosstalk of mTOR/S6K1 and Hedgehog pathwaysY Wang, Q Ding, CJ Yen, W Xia, JG Izzo, JY Lang, CW Li, JL Hsu, ...Cancer cell 21 (3), 374-387, 20123962012
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept